Please assess the completion status of the following clinical trial:

Trial Title: Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Histological diagnosis of breast cancer.~* Node positive operable breast cancer (stages II-III).~* Breast cancer surgery, consisting of radical mastectomy or conservative surgery, plus lymphadenectomy with at least 6 extirpated nodes. Surgery must have happened in the 8 weeks prior to randomisation.~* Age \>=18 and \<= 70 years old.~* Negative pregnancy test. Adequate contraceptive method during the study participation.~* Performance status of 90-100 (Karnofsky index) or ECOG \<=1.~* Haemoglobin \>= 10 g/dl; neutrophils \> 1,500/cc; platelets \> 100,000/cc.~* Adequate hepatic function with bilirubin, SGOT and SGPT \< 1.5 x upper normal limit (UNL).~* Adequate cardiac function documented by left ventricular ejection fraction (LVEF).~* Adequate renal function with creatinine \< 1.5 mg/dl.~Exclusion Criteria:~* Previous chemotherapy, hormone therapy and/or radiotherapy for breast cancer.~* Bilateral breast cancer. Lobular in situ carcinoma.~* Previous or current malignancies, except for basal skin carcinoma, cervical in situ carcinoma or superficial bladder carcinoma, adequately treated.~* History of arrhythmias and/or congestive heart failure or cardiac blocking grade 2-3; history of myocardial infarction in 6 months before recruitment.~* Inability for treatment and study compliance.~* Pregnant or lactating women.~* Active infection.~* History of hypersensitivity to cremophor or cyclosporine.~* Pre-existing grade 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria \[NCI CTC\]).~* Hormonal receptor status not determined.~* Any other criteria which, in investigator's opinion, may jeopardize patient's security or compliance.~* Administration of other investigational product in the 30 days prior to randomisation; current participation in another clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluorouracil+Epirubicin+Cyclophosphamide (Type: ACTIVE_COMPARATOR): 5-FU+4-Epirubicin+Cyclophosphamide
- FEC followed by Paclitaxel (Type: EXPERIMENTAL): 5-FU+4-Epirubicin+Cyclophosphamide

Based on this trial design, predict the completion outcome and termination type (if applicable).